Letrozole Femara for Breast Cancer CAS 112809-51-5

• Product NameLetrozole Femara for Breast Cancer CAS 112809-51-5
  CAS No.112809-51-5
  Purity99%
  Min Quantity500Kilograms
  Price1~100
• View Contact Detail

• 
  Molecular Structure

Detailed Description

Quick Details:
Alias: Femara, Lelrozol, TROZET,Letroz,Lelroz, letrozolex
CAS Registry Number:112809-51-5
Purity: 98%
MF: C17H11N5
MW: 285.3
Appearance: White crystalline powder.
Grade:Pharmaceutical Grade
Sotre at: Cool dry place
Usage:Used as API in Treatment of breast disease.


Description :
Letrozole Femara is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.Letrozole Femara is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs, like tamoxifen. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.

• 
• Letrozole Femara for Breast Cancer CAS 112809-51-5